

Esam Z. Dajani, Ph.D., FACG

President, IDDC Corporation

Adjunct Professor of Medicine, Loyola University Chicago

1549 RFD, Long Grove, Illinois 60047-9532

Phone: (847) 634-9586; Fax: (847) 634-3349; E-mail: EsamD@comcast.net; EsamD@aol.com

Web Site: www.edajani.com

Publications: B. Books and Chapters

1. Moss JN, Dajani EZ: Antihyperlipidemic agents. In: *Screening Methods in Pharmacology*, Vol. 2. Eds. Turner RA, Hebborn P, Acad. Press, NY, PP 121-143, 1971.
2. Dajani EZ: The actions of prostaglandins on the gastrointestinal tract. In: *Prostaglandins in the Upper Gastrointestinal Tract*. Vol. 5, in Therapeutics Today Series, Adis Press, Australasia Pty., Ltd., PP 9-18, 1986.
3. Dajani EZ: Mucosal protective activities of misoprostol in man: An overview. In: *Gastrointestinal Cytoprotection by Prostaglandins: Focus on Misoprostol*. Eds. Bianchi Porro G, Dajani EZ, Cortina International-Verona, Italy. PP 21-32, 1987.
4. Dajani EZ, Wehrschütz E: Prostaglandins and the integrity of the gastrointestinal mucosa. In: *Erosionen in Magen und Duodenum*. Eds. Van Maercke Y, Bergemann W. VCH Publishers, New York, NY, PP 211-216, 1987.
5. Dajani EZ: Perspectives on the pharmacology of misoprostol. In: *Ulcer Disease: New Aspects of Pathogenesis and Pharmacology*. Eds. Szabo S, Pfeifer C. CRC Press, Boca Raton, Florida, Chapter 27, PP 321-334, 1989.
6. Dajani EZ, Gallo-Torres H: Pharmaceutical industry perspective of the human investigation of peptic ulcer disease. In: *Ulcer Disease: Investigation and Basis for Therapy*. Eds. Szabo S, Swabb E, Marcel Dekker, New York, PP 459-485, 1991.
7. Dajani EZ: Prostaglandins and esophageal mucosal integrity. In: *Advances in Drug Therapy of Gastroesophageal Reflux Disease*. Ed. Scarpignato E, Karger, Basel PP 307-316, 1992.
8. Dajani EZ, Agrawal NM: Prevention and treatment of gastric and duodenal ulcers induced by nonsteroidal anti-inflammatory drugs. In: *NSAIDs - Mechanisms and Clinical Use*. Eds. Lewis AJ, Furst D, Marcel Dekker, New York, PP 159-170, 1994.
9. Agrawal NM, Dajani EZ: Drug-induced ulcers. In: *Gastrointestinal Pharmacology and Therapeutics*. Eds. Friedman J, Jacobson ED, McCallum R, Lippincott-Raven Publishers, Hagerstown, Maryland, Chapter 5, PP 55-63, 1997.
10. Dajani EZ, Dajani NE, Shahwan TG: Over-the-Counter Drugs. In: *Encyclopedia of Gastroenterology*. Ed. Johnson LR, Elsevier Science., PP 16-23, 2004.

Publications: C. Research Papers

1. Dajani EZ: Studies on the toxicology and central nervous system pharmacology of ethylene glycol monomethyl ether in rats and mice. Unpublished Ph.D. thesis, Purdue University, 1968.
2. Dajani EZ, Driskill DR, Bianchi RG, Collins PW: Comparative gastric antisecretory and antiulcer effects of Prostaglandin E₁ and its methyl ester in animals. *Prostaglandins* 10:205-216, 1975.
3. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Influence of the position of the side chain hydroxy group on the gastric antisecretory and anti-ulcer actions of E₁ prostaglandin analogs. *Prostaglandins* 10:733-745, 1975.
4. Sanvordeker DR, Dajani EZ: In vitro adsorption of diphenoxylate hydrochloride on activated charcoal and its relationship to pharmacological effects of the drug in vivo. *J Pharm Sci* 64:1877-1879, 1975.
5. Dajani EZ, Roge EAW, Bertermann RE: Effects of E-prostaglandins, diphenoxylate and morphine on intestinal motility in vivo. *Europ J Pharmacol* 34:105-113, 1975.
6. Collins PW, Dajani EZ, Bruhn MS, Brown CH, Palmer JR, Pappo R: Influence of the position of the side chain hydroxyl group on the biological properties of prostaglandins. *Tetrahedron Letters* 48:4217-4220, 1975.
7. Bruhn M, Brown CH, Collins PW, Palmer JR, Dajani EZ, Pappo R: Synthesis and properties of 16-hydroxy analogs of PGE₂. *Tetrahedron Letters* 4:235-238, 1976.
8. Dajani EZ, Callison DA, Bianchi RG, Driskill DR: Gastric antisecretory effects of E-prostaglandins in rhesus monkeys. *Dig Dis and Sci* 21:1020-1028, 1976.
9. Dajani EZ, Callison DA: Gastric antisecretory actions of 15(S) 15-methyl prostaglandin E₂ methyl ester and natural prostaglandin E₂ in rhesus monkeys. *Prostaglandins* 11:799-808, 1976.
10. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: SC-29333, a potent inhibitor of canine gastric secretion. *Dig Dis Sci* 21:1049-1057, 1976.
11. Mackerer CR, Clay GA, Dajani EZ: Loperamide binding to opiate receptor sites of brain and myenteric plexus. *J Pharmacol Exp Therap* 199:131-140, 1976.

12. Dajani EZ, Rozek LF, Sanner JH, Miyano M: Synthesis and biological evaluation of W-homologues of prostaglandin E₁. *J Med Chem* 19:1007-1010, 1976.
13. Adelstein GW, Yen CH, Dajani EZ, Bianchi RG: 3,3-Diphenyl-3 (2-alkyl-1,3,4-Oxadiazol-5-yl) propylcycloalkylamines: A novel series of anti-diarrheal agents. *J Med Chem* 19:1221-1225, 1976.
14. Dajani EZ, Bianchi RG, East PF, Bloss JL, Adelstein GW, Yen CH: The pharmacology of SC-27166: A novel anti-diarrheal agent. *J Pharmacol Exp Therap* 203:512-526, 1977.
15. Dajani EZ, Driskill DR: Effects of 7-oxa-13-prostynoic acid (7-OPyA) and prostaglandin E₁ methyl ester on canine gastric secretion. *Prostaglandins* 14:659-665, 1977.
16. Collins PW, Dajani EZ, Driskill DR, Bruhn MS, Jung CJ, Pappo R: Synthesis and gastric antisecretory properties of 15-deoxy, 16-hydroxy E-prostaglandin analogs. *J Med Chem* 20:1152-1159, 1977.
17. Mackerer CR, Brougham LR, East PF, Bloss JL, Dajani EZ, Clay GA: The binding of SC-27166 [2-[3,3-diphenyl-3-(2-methyl-1,3,4-oxadiazol-5-yl)propyl]-azabicyclo [2.2.2] Octane], a new antidiarrheal agent, to opiate receptor sites of brain and myenteric plexus. *J Pharmacol Exp Therap* 203:527-538, 1977.
18. Dajani EZ, Callison DA, Bertermann RE: Effects of E-prostaglandins on canine gastric potential difference. *Dig Dis Sci* 23:436-442, 1978.
19. Dajani EZ, Callison DA, Bianchi RG: Gastric antisecretory effects of propantheline bromide and metiamide in rhesus monkeys. *Arch Int Pharmacodyn Therap* 234:107-117, 1978.
20. Dajani EZ, Driskill D: Effect of oral and intravenous propantheline bromide on pentagastrin-stimulated canine gastric secretion. *Arch Int Pharmacodyn Therap* 233:243-250, 1978.
21. Colton DG, Driskill DR, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333, an inhibitor of gastric secretion, on canine gastric mucosal blood flow and serum gastrin levels. *Arch Int Pharmacodyn et Therap* 236:86-95, 1978.
22. Dajani EZ, Bertermann, RE, Roge EAW, Schweingruber FL, Woods EM: Canine gastrointestinal motility effects of prostaglandin F₂ alpha in vivo. *Arch Int Pharmacodyn Therap* 237:16-24, 1979.
23. Dajani EZ, Bianchi RG, Calhoun DW: Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the prevention of stress ulcer formation in rats. *J Pharmacol Exp Therap* 210:373-377, 1979.

24. Colton DG, Callison DA, Dajani EZ: Effects of prostaglandin E₁ derivative, SC-29333, and aspirin on gastric ionic fluxes and potential difference in dogs. *J Pharmacol Exp Therap* 210:283-288, 1979.
25. Dajani EZ, Woods EM, Roge EAW, Bertermann RE, Schweingruber FL: Naloxone reversal of drug-induced diarrhea in mice. *Arch Int Pharmacodyn Therap* 240:340-350, 1979.
26. Dajani EZ, Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory effect of carbenoxolone, aldosterone and desoxycorticosterone in rats. *Arch Int Pharmacodyn Therap* 242:128-138, 1979.
27. Gullikson GW, Dajani EZ, Bianchi RG: Inhibition of intestinal secretion in the dog: A new approach for the management of diarrheal states. *J Pharmacol Exp Therap* 219:591-597, 1981.
28. Dajani EZ, Driskill DR, Bianchi RG, Phillips EL, Woods EM, Colton DG, Collins PW, Pappo R: Effect of prostaglandin analogue, SC-30249, on canine gastric secretion. *Drug Dev Res* 3:339-347, 1983.
29. Collins PW, Dajani EZ, Pappo R, Gasiiecki AF, Bianchi RG, Woods EM: Synthesis and gastric antisecretory properties of 4,5 unsaturated derivatives of 15-deoxy-16-hydroxy-16-methyl prostaglandin E₁. *J Med Chem* 26:786-790, 1983.
30. Dajani EZ, Nissen CA: Investigations of the gastrointestinal cytoprotective effects of misoprostol: Clinical efficacy overview. *Dig Dis Sci* 30:194S-200S, 1985.
31. Collins PW, Pappo R, Dajani EZ: Chemistry and synthetic development of misoprostol. *Dig Dis Sci* 30:114S-117S, 1985.
32. Sontag SJ, Mazure PA, Pontes JF, Beker SG, Dajani EZ: Misoprostol in the treatment of duodenal ulcer: A multi-center, double-blind, placebo-controlled study. *Dig Dis and Sci* 30:159S-163S, 1985.
33. Agrawal NM, Saffouri B, Kruss DM, Callison DA, Dajani EZ: Healing benign gastric ulcer: A placebo-controlled comparison of two misoprostol dosage regimens. A synthetic analog of prostaglandin E₁. *Dig Dis Sci* 30:164S-170S, 1985.
34. McGuigan JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer. *Dig Dis Sci* 31:120S-125S, 1986.

35. Dajani EZ: Is peptic ulcer a prostaglandin deficiency disease? An editorial. *Human Pathology* 17:106-107, 1986.
36. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Cytoprotection against ethanol-induced gastric mucosal damage by a synthetic prostaglandin: A double blind endoscopic study in human subjects. *Gastrointestinal Endoscopy* 32:67-70, 1986.
37. Dajani EZ: Prostaglandins, ASA and mucosal damage. *Arzneim Forsch/Drug Research* 36:1150-1151, 1986.
38. Gullikson GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol attenuates aspirin-induced changes in potential difference and associated damage in canine Heidenhain pouches. *Clinical Invest Med.* 10: 145-151, 1987.
39. Bertaccini G, Dajani E, Paoletti R, Watkinson G: Prostaglandins in gastroenterology--Focus on Misoprostol--Forward. *Prostaglandins* 33 (Suppl.): 1, 1987.
40. Dajani EZ: Perspective on the gastric antisecretory effects of misoprostol in man. *Prostaglandins* 33 (Suppl.): 68-77, 1987.
41. Reimann HJ, Lewin T, Schmidt U, Wendt P, Blueml G, Dajani EZ: Misoprostol prevents damage to the gastric mucosa by stabilizing the mast cells. *Prostaglandins* 33 (Suppl.):105-116, 1987.
42. Dajani EZ: Overview of the mucosal protective effects of misoprostol in man. *Prostaglandins* 33 (Suppl.):117-129, 1987.
43. Godiwala T, Agrawal NM, Groot K, Arimura, Dajani EZ: Is cytoprotection by misoprostol against ethanol-induced gastric mucosal injury in man mediated by somatostatin? *Prostaglandins* 33 (Suppl.):130-131, 1987.
44. Davis GR, Fordtran JS, Dajani EZ: Dose-response, meal-stimulated gastric antisecretory study of prostaglandin E₁ analog, misoprostol, in man. *Dig Dis Sci* 33:298-302, 1988.
45. Agrawal NM, Godiwala T, Arimura A, Groot K, Dajani EZ: Protective effects against alcohol insult: Does somatostatin play any role? *Post Graduate Medical Journal* 64 (Suppl. 1):15-18, 1988.
46. Dajani EZ: Prostaglandins: Pharmacology, mechanism and applications in peptic ulcer disease. *Chinese J Clin Pharmacol* 5 (2):102-117, 1989.
47. Dajani EZ, Agrawal NM: Protective and therapeutic effects of prostaglandins. *Clin Pharmacol Res* 9(6): 359-369, 1989.

48. Agrawal NM, Dajani EZ: Treatment and prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. *Clin Pharmacol Res* 9 (6): 347-357, 1989
49. Dajani EZ: Mucosal defense and concept of cytoprotection. An Editorial. *Modern Pathology* 3:3-4, 1990.
50. Agrawal NM, Dajani EZ: Options in the treatment and prevention of NSAID-induced gastroduodenal mucosal damage. *J Rheumatology* 17 (Suppl): 7-11, 1990.
51. Dajani EZ, Agrawal NM: Nonsteroidal anti-inflammatory drug-induced gastrointestinal damage in the elderly: Pathogenesis and therapeutic considerations. *Internal Medicine for the Specialist* 11 (9): 91-110, 1990.
52. Dajani EZ, Wilson DM, Agrawal NM: Prostaglandins: An overview of the worldwide clinical experience. *J Assoc Acad Min Physicians* 2:23-25, 1991.
53. Dajani EZ, Penin VA, Sokolov LK, Vahtangishvilli R, Bogdanov A, Afonskaya N, Ivanishvilli L, Zharova Y., Efremova I: Misoprostol and dalargin for the in-patient treatment of duodenal ulcer in the U.S.S.R. *J Assoc Acad Min Physicians* 2:18-22, 1991.
54. Dajani EZ: Review of book entitled "Clinical Investigation of gastric function." *Gastroenterology* 100:1478-1479, 1991.
55. Agrawal NM, Patel R, Mahatma M, Dajani EZ: Nonsteroidal anti-inflammatory drugs and acute upper gastrointestinal bleeding: A prospective study. *J Assoc Acad Min Physicians* 2:64-66, 1991.
56. Dajani EZ: Misoprostol: Pharmacology, pharmacokinetics and mechanisms of action. *Experimental and Clinical Gastroenterology* 1:97-106, 1991.
57. Mahatma M, Agrawal N, Dajani EZ, Nelson S, Nakamura C, Sitton J: Misoprostol but not antacid prevents endotoxin-induced gastric mucosal injury: Role of tumor necrosis factor-alpha. *Dig Dis Sci* 36:1562-1568, 1991.
58. Dajani EZ, Straus E: Editorial Overview. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A special edition of the *J Assoc Acad Minority Physicians* 3:69, 1992.
59. Dajani EZ, Trotman BW: Drugs for the treatment of peptic ulcers. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A special edition of the *J Assoc Academic Minority Physicians* 3:78-88, 1992.
60. Arakawa T, Kobayashi K, Dajani EZ: Refractory peptic ulcers. In: *Updates in Acid Peptic Disorders*. Eds. Dajani EZ, Straus EW: A Special edition of the *J Assoc for Academic*

Minority Physicians 3: 95-102, 1992.

61. Agrawal NW, Dajani EZ: Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. *J Assoc Acad Minority Physicians* 3: 142-148, 1992.
62. Larsen KR, Dajani EZ, Ives MM: Anti-ulcer drugs and gastric mucosal injury: Effects of misoprostol, 16, 16-dimethyl PGE2 and cimetidine on hemodynamics and metabolic rate in the canine gastric mucosa. *Dig Dis Sci* 37: 1029-1038, 1992.
63. Dajani EZ, Wang B, Pei Y, Pan G, Chen S, Zheng Z, Li Y, Zhu W, Wang J, Yuan S, Yu Y, Yao ZJ: Misoprostol in the treatment of duodenal ulcers in the People's Republic of China: A comparative, double-blind multicenter study. *Drug Development Research* 27: 415-423, 1992.
64. Dajani EZ: Omega-3 fatty acids and bowel cancer. *Gastroenterology* 104:1239-1240, 1993.
65. Dajani EZ: Future treatment of peptic ulcer: Is there room for the anti-infective drugs? An editorial. *J Physiology and Pharmacology* 44:3-6, 1993.
66. Juhl CO, Vinter-Jensen L, Jensen LS, Nexø E, Djurhuus JC, Dajani EZ: Systemic treatment with recombinant human epidermal growth factor accelerates healing of sclerotherapy-induced esophageal ulcers and prevents esophageal stricture formations in pigs. *Dig Dis Sci* 39: 2671-2678, 1994.
67. Juhl CO, Vinter-Jensen L, Jensen LS, Nexø E, Djurhuus JC, Dajani EZ: Biomechanical properties of the oesophagus damaged by sclerotherapy: An impedance planimetric study in minipigs. *Scand J Gastroenterol* 29: 867-873, 1994.
68. Vinter-Jensen L, Frokiaer J, Jorgensen PE, Marqversen J, Rehling M, Dajani EZ, Nexø E: Tissue distribution of ¹³¹I-labelled epidermal growth factor in pig visualized by dynamic scintigraphy. *J Endocrinology* 144: 5-12, 1995.
69. Dajani EZ, Agrawal NM: Prevention on nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: Role of mucosal protective and gastric anti-secretory drugs. *Digestive Diseases* 12 (Suppl 1): 46-61, 1995.
70. Dajani EZ, Agrawal NM: Prevention and treatment of NSAID-induced ulcers: An update. *J Physiol Pharmacol* 46: 3-16, 1995.
71. Vinter-Jensen L, Juhl CO, Eika B, Gregersen H, Dajani EZ: Epidermal growth factor attenuates the sclerotherapy associated biomechanical properties of the oesophagus: An experimental study in minipigs. *Scand J Gastroenterol* 30: 614-619, 1995.

72. Vinter-Jensen L, Juhl CO, Rehfeld JF, Poulsen SS, Dajani EZ, Nexo E: Chronic treatment with epidermal growth factor induces hypergastrinemia in pigs. *Scand J Gastroenterol* 30: 422-427, 1995.
73. Vinter-Jensen L, Juhl CO, Djurhuus JC, Dajani EZ, Teglbjaerg PS, Uvelius, Nexo E: Ureteric growth in Gottingen minipig induced by epidermal growth factor. A case report. *Scand J Urol Nephrol Suppl* 172: 109-115, 1995.
74. Juhl CO, Vinter-Jensen L, Jensen LS, Dajani EZ, Nexo E: Preventive effects of recombinant human epidermal growth factor on the esophageal epithelium in pigs subjected to sclerotherapy. *Europ J Hepatol Gastroenterol* 17: 823-828, 1995.
75. Vinter-Jensen L, Juhl CO, Djurhuus JC, Poulson SS, Dajani EZ, Brown KD, Orntoft TF, Teglbjaerg PS, Nexo E: Chronic Systemic treatment with epidermal growth factor in pigs causes pronounced urothelial growth with accumulation of glycoconjugates. *Am J Pathol* 147: 1330-1338, 1995.
76. Juhl CO, Vinter-Jensen L, Myhre-Jensen O, Jensen LS, Dajani EZ: Systemic treatment with epidermal growth factor in pigs induces anemia in Gottington pigs. *Clinical Sciences* 89: 453-458, 1995.
77. Vinter-Jensen L, Juhl CO, Poulsen SS, Djurhuus JC, Dajani EZ, Nexo E: Chronic administration of epidermal growth factor to pigs induces growth especially of the urinary tract with accumulation of epithelial glycoconjugates. *Lab Invest* 73: 788-793, 1995.
78. Juhl CO, Vinter-Jensen L, Poulsen SS, Orntoft TF, Dajani EZ: Chronic treatment with epidermal growth factor causes esophageal hyperplasia in pigs and rats. *Dig Dis Sci* 40: 2717-2723, 1995.
79. Dajani EZ: Prostaglandins, NSAIDs and gastrointestinal mucosal injury: Can we identify patients at risk of NSAID-induced gastric injury? An Editroial. *Am J Gastroenterol* 91 (5): 835-836, 1996.
80. Vega KJ, Bollu J, Dajani EZ, Trotman BW: Idiopathic esophageal ulceration in HIV patients. *J Assoc Acad Min Phys* 74 (4): 93-98, 1996.
81. Vinter-Jensen L, Juhl CO, Frystyk J, Dajani EZ, Oksbjerg N, FlyvbjergN: The effects of epidermal growth factor (EGF) on circulating levels on insulin like growth factor I(IGF-I) and IGF binding proteins (IGFBPs) in adult Goettingen minipigs. *J Endocrinol* 151: 401-407, 1996.

82. Gregersen H, Vinter-Jensen L, Juhl CO, Dajani EZ: Impedance planimetric characterization of distal esophagus in the Goettingen minipigs. *J Biomech* 29: 63-68, 1996.
83. Vinter-Jensen L, Juhl CO, Dajani EZ, Nielsen M, Djurhuus JC: Chronic systemic treatment with epidermal growth factor induces smooth muscle cell hyperplasia and hypertrophy in the urinary tract of mature Goettingen minipigs. *British J Urology* 79: 532-538, 1997.
84. Vinter-Jensen L, Juhl CO, Stubbe P, Poulsen SS, Nexø E: Systemic treatment with epidermal growth factor in pigs induces ductal proliferations in the pancreas. *Gastroenterology* 113: 1367-1374, 1997.
85. Dajani EZ: Gastrointestinal Toxicity of over-the-counter analgesics. An Editorial. *Am J Gastroenterol* 93(7): 1020-1022, 1998.
86. Larsen KR, Dajani EZ, Dajani NE, Dayton MT, Moore JG: Effects of tolcapone, a catechol-o-methyl transferase inhibitor, and Sinemet on intestinal electrolyte and fluid transport in conscious dogs. *Dig Dis Sci* 43(8): 1806-1813, 1998.
87. Adeoti AG, Vega KJ, Dajani EZ, Trotman BW, Kloser PC: Idiopathic esophageal ulcerations in HIV infected patients. Successful treatment with misoprostol and viscous Lidocaine. *Am J Gastroenterol* 93(11): 2069-2074, 1998.
88. Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shahwan TG, Neeleman SD, Taylor MS, Dayton MT, Mir GN: CT-3 [1',1'-dimethyl-heptyl-Delta-8-THC-11-oic acid]: A novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. *J Pharmacol Exp Therap* 291: 31-38, 1999.
89. Dajani EZ: Gastroesophageal reflux disease (GERD): Pathophysiological and pharmacological considerations. *J Assoc Acad Minority Physicians* 11: 7-11, 2000.
90. Trotman BW, Boyce JG, Dajani EZ, Kamholz SL, Rayford PL, Scott VF: Highlights of the 13th Annual Scientific Meeting of the Association for Academic Minority Physicians. *J Assoc Acad Minority Physicians* 11: 3-5, 2000.
91. Dajani EZ, Klamut M: Therapeutic approaches for gastric and duodenal ulcers: An update. *Expert Opinion on Investigational Drugs* 90: 1537-1544, 2000.
92. Dajani EZ, Agrawal NM: Selective COX-2 inhibitors and gastrointestinal mucosal injury: Pharmacological and therapeutic considerations. *J Assoc Acad Minority Physicians* 11: 28-31, 2000.
93. Trotman BW, Boyce JG, Dajani EZ, Davidson EC, Scott VF: Highlights of the 14th Annual Scientific Meeting of the Association for Academic Minority Physicians, 2000. *J Assoc Acad Minority Physicians* 12: 95-97, 2001.

94. Dajani EZ, Shahwan TG, Dajani, NE: Statins, platelet aggregation and coronary heart disease. *J Assoc Acad Minority Physicians* 13: 27-31, 2002.
95. Trotman BW, Scott VF, Dajani EZ, Davidson EC, Kamholz SL: Highlights of the 15th Annual Scientific Meeting of the Association for Academic Minority Physicians, 2001. *J Assoc Acad Minority Physicians* 13: 6-8, 2002.
96. Dajani EZ, Shahwan TG, Dajani, NE: Prostaglandins and the Brain-Gut Axis. *J Physiology and Pharmacology* 54: 155-164, 2003.
97. Konturek, SJ, Pawlik WW, Dajani EZ: Brain-Gut Axis in gastrointestinal system: Introductory Remarks. *J Physiology and Pharmacology* 54: 3-8, 2003.
98. Dajani EZ, Dajani ME: Are U.S. cosmetic regulatory policies keeping consumers safe? Update (Published by Food and Drug Laws Institute) 6: (November/December): 22-24, 2005.
99. Dajani EZ, Islam K: Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors. *J Physiol Pharmacol* 59 (supplement 2): 117-33, 2008.

Abstracts/Presentations:

1. Dajani EZ: Studies on the pharmacology of the industrial solvent methyl cellosolve. Society of Experimental Biology and Medicine. Indianapolis, Indiana. October 1968.
2. Dajani EZ, Mennear JH: Gas chromatographic assay for ethylene glycol monomethyl ester. *Toxicol Appl Pharmacol* 14(3): 618, 1969.
3. Dajani EZ: Experimental cholelithiasis: Studies on the mouse and hamster gallstone models. An invited lecture presented at the Gastrointestinal Pharmacology Group Symposium on Bile. Philadelphia, Pennsylvania. November 1970.
4. Dajani EZ: The technicians' role in toxicological studies. An invited lecture presented at the AALAS Symposium on Laboratory Animal Considerations in Toxicology and Related Disciplines. New Brunswick, New Jersey. June 1972.
5. Dajani EZ: Gastric antisecretory and antiulcer actions of E-prostaglandin analogs. An invited lecture presented at the Department of Medicine (Gastroenterology), University of California, San Francisco, California. April 1974.
6. Dajani EZ, Roge EAW, Bertermann RE: The effect of prostaglandin E₁ methyl ester and diphenoxylate on canine duodenal motility in vivo. Presented at the Midwest Pharmacology Meeting. Ann Arbor, Michigan. May 1975.
7. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Studies on the biological properties of a prostaglandin analog, SC-29333, a potent inhibitor of gastric secretion. Presented at the International Conference on Prostaglandins. Florence, Italy. May 1975.
8. Collins PW, Pappo R, Dajani EZ: Application of 1,4 addition reactions to the synthesis of novel prostaglandins. Presented at the International Conference on Prostaglandins. Florence, Italy. May 1975.
9. Dajani EZ, Bianchi RG, Adelstein GW, Yen CH: Studies on the biological properties of SC-27166, a novel antidiarrheal agent. Philadelphia GI Research Forum. Philadelphia, Pennsylvania. October 1975.
10. Dajani EZ, Driskill DR, Bianchi RG, Collins PW, Pappo R: Studies on the pharmacology of SC-29333, a potent gastric antisecretory prostaglandin. Philadelphia GI Research Forum. Philadelphia, Pennsylvania. October 1975.

11. Adelstein GW, Yen CH, Dajani EZ: Synthesis and biology of a novel series of antidiarrheal agents. Am Chem Soc Meeting. Mexico City, Mexico, 1975.
12. Pappo R, Collins PW, Bruhn MS, Palmer JR, Dajani EZ: Synthesis and biological properties of 16-hydroxy prostaglandin analogs. Winter Prostaglandin Conference. Vail, Colorado. January 1976.
13. Dajani EZ, Callison DA, Bianchi RG, Driskill DR: Gastric antisecretory effects of E-prostaglandins in conscious monkeys. Federation Proceedings 35: 539, 1976.
14. Dajani EZ: Effects of E-prostaglandins on the gastric mucosal barrier. An invited presentation at the Gastrointestinal Pharmacology Symposium entitled "Drugs and the Gastric Mucosal Barrier." Groton, Connecticut. October 1976.
15. Callison DA, Dajani EZ, Bertermann RE: Effects of E-prostaglandins on canine gastric potential differences. Federation Proceedings 36:595, 1977.
16. Dajani EZ: Drug research in the pharmaceutical industry: A pharmacologist's point of view. An invited series of continuing medical and pharmaceutical education lectures presented at the Kuwait Ministry of Health, Kuwait. November 1977.
17. Driskill DR, Colton DG, Phillips EL, Poy P, Dajani EZ: Effect of SC-29333 on gastric mucosal blood flow and serum gastrin in the dog. Federation Proceedings 37: 459, 1978.
18. Callison DA, Dajani EZ, Bianchi RG: Gastric antisecretory actions of propantheline bromide and metiamide in conscious rhesus monkeys. Federation Proceedings 37: 460, 1978.
19. Dajani EZ: Perspective on the pharmacology of antidiarrheal drugs. An invited presentation at a 1978 ASPET Symposium entitled "Current Concepts of Gastrointestinal Motility." Atlantic City, New Jersey. April 1978.
20. Dajani EZ, Roge EAW, Bertermann RE, Schweingruber FL: Gastrointestinal motility effects of PGF₂ alpha in the dog. 7th International Congress of Pharmacology. Paris, France. July 1978.
21. Dajani EZ, Roge EW, Bertermann RE, Schweingruber FL: Reversal of gastrointestinal motility actions of PGF₂ alpha by naloxone. 7th International Congress of Pharmacology. Paris, France. July 1978.
22. Bianchi RG, Dajani EZ, Calhoun DW: Synergistic actions of propantheline bromide, cimetidine and thiopropazate in the prevention of stress ulcer formation in rats. Pharmacologist 20:209, 1978.

23. Dajani EZ: Pharmacology of anticholinergic drugs. Invited lecture presented at The Northern Illinois Orthodontic Study Group. Chicago, Illinois. October 1978.
24. Adelstein GW, Yen CH, Dajani EZ, Bianchi RG: Potent analogs of Lomotil; separation of constipating and analgesic properties. Amer Chem Soc Great Lakes Regional Meeting. Rockford, Illinois. June 1979.
25. Dajani EZ: Perspective on the pharmacology of gastric antisecretory and antiulcer drugs. An invited lecture presented at the Amer Chem Soc Symposium on Peptic Ulcer, Great Lakes Regional Meeting. Rockford, Illinois. June 1979.
26. Woods EM, Dajani EZ, Roge EW, Bertermann RE, Schweingruber FL: Naloxone reversal of drug-induced diarrhea in mice. *Pharmacologist* 21:175, 1979.
27. Dajani EZ, Bianchi RG, Casler JJ, Weet JF: Gastric antiulcer and antisecretory effects of carbenoxolone, aldosterone and desoxycorticosterone in rats. *Pharmacologist* 21:176, 1979.
28. Bianchi RG, Dajani EZ, Casler JJ, Calhoun DW: Synergistic actions of propantheline bromide with cimetidine and thiopropazate hydrochloride in the inhibition of gastric secretion in rats. *Pharmacologist* 21:176, 1979.
29. Dajani EZ: Prostaglandins and the gut: An update. An invited lecture presented at the ASPET Symposium entitled "Recent Developments in Gastrointestinal Pharmacology." Portland, Oregon. 1979.
30. Dajani EZ: Perspective on the pharmacology of antiulcer drugs: An update. Grand Rounds presented at the Department of Medicine, Northwestern University. Chicago, Illinois. November 1979.
31. Driskill DR, Dajani EZ, Phillips EL, Collins PW, Pappo R: Effects of a prostaglandin analogue, SC-30249, on canine gastric secretion. *Federation Proceedings* 39(3): 563, 1980.
32. Dajani EZ: Comparison between the pharmacology of gastric and duodenal antiulcer drugs. An invited presentation at a symposium entitled "Duodenal and Gastric Ulcers - Pathogenesis and Pharmacology," co-sponsored by Society of Pathology and ASPET. Anaheim, California. April 1980.
33. Bianchi RG, Dajani EZ, Casler JJ: Gastric antiulcer and antisecretory effects of bismuth salts in the rat. *Pharmacologist* 22:168, 1980.
34. Gullikson GW, Dajani EZ, Bianchi RG: Reversal of deoxycholate-induced intestinal fluid

secretion by lidamidine. *Pharmacologist* 22:168, 1980.

35. Yen CH, Bianchi RG, Dajani EZ: Synthesis and biological activities of substituted quinuclidines. Amer Chem Soc Meeting. Chicago, Illinois. January 1981.
36. Dajani EZ: Pharmacology of the prostaglandin analogue SC-29333. International Congress on Stomach Diseases, University of Antwerp. Antwerp, Belgium. May 1981.
37. Dajani EZ: Prostaglandins and the gastrointestinal tract. Grand Rounds, Hines VA Hospital. Hines, Illinois. May 1981.
38. Kessler L, Bianchi RG, Callison DA, Dajani EZ: Prevention of duodenal ulcer formation in the cat by E-prostaglandins. *Pharmacologist* 23:121, 1981.
39. Bianchi RG, Casler JJ, Dajani EZ: Gastric antisecretory and antiulcer activity of SC-29333: A synthetic E-prostaglandin analog. *Pharmacologist* 23:121, 1981.
40. Gullikson GW, Jasty V, Dajani EZ: Effect of lidamidine on deoxycholate-induced histological and permeability changes in canine jejunum. *Pharmacologist* 23:122, 1981.
41. Dajani EZ: Perspectives on the pharmacology of antiulcer drugs. An invited lecture presented at a symposium entitled "Recent Advances Against Duodenal and Gastric Ulcer Disease," 13th Lithuanian American Medical Association. Chicago, Illinois. September 1981.
42. Collins PW, Dajani EZ, Pappo R, Gasiecki AF, Bianchi RG, Woods EM: Synthesis and gastric antisecretory properties of 4,5-unsaturated derivatives of 15-deoxy-16-hydroxyl-16-methyl prostaglandin E₁. *Amer Chem Soc* 183:62, 1982.
43. Pitzele BS, Kellar P, Kessler L, Sanner J, Woods EM, Dajani EZ: Quaternary ammonium analogs of an H₂-receptor antagonist. *Amer Chem Soc* 183: 58, 1982.
44. Dajani EZ: Perspectives on the pharmacology of misoprostol, a synthetic PGE₁ analogue. An invited lecture presented at the Gordon Research Conference on Medicinal Chemistry, Colby-Sawyer College. New London, New Hampshire. August 1982.
45. Dajani EZ, Collins PW, Bianchi RG, Woods EM, Colton DG, Driskill DR, Pappo R: Gastrointestinal pharmacology of misoprostol: A novel antiulcer agent. Invited lecture, Department of Pharmacology, University of Wisconsin. Madison, Wisconsin. April 1983.
46. Gullikson GW, Anglin C, Kessler L, Smeach S, Crowder S, Bauer R, Dajani EZ: Misoprostol prevents aspirin-induced damage in canine Heidenhain pouches. *Gastroenterology* 84:1176, 1983.
47. Dajani EZ: Prostaglandins. An invited presentation, Chicago Society of

Gastroenterology. Chicago, Illinois. March 1984.

48. Dajani EZ: Prostaglandins in gastroenterology. An invited lecture (principal speaker), European Association for Gastro-Camera, Diagnosis and Endoscopy. Innsbruck, Austria. March 1984.
49. Collins PW, Gasielki AF, Decktor D, Dajani EZ, Woods EM, Bianchi RG: Alpha chain unsaturated derivatives of 16-hydroxy prostaglandins. Amer Chem Soc, National Medicinal Symposium, June 1984.
50. Dajani EZ: Antidiarrheal drugs. An invited presentation delivered at a symposium entitled "Newer Gastrointestinal Drugs," sponsored by The Amer Chem Soc. Philadelphia, Pennsylvania. August 1984.
51. Tapper EJ, Dajani EZ, Polk RC: Dose-response duodenal ulcer healing by prostaglandin E₁ analog. International Congress of Gastroenterology. Lisbon, Portugal. September 1984.
52. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Cytoprotection by prostaglandin E₁ analog on ethanol-induced gastric mucosal damage in man. Amer J Gastroenterology 79: 824, 1984.
53. Dajani EZ: Non-prostanoids as cytoprotective agents. An invited presentation, Mexican Gastroenterological Association Meeting. Guadalajara, Mexico. December 1984.
54. Dajani EZ: Mucosal cytoprotection: Clinical models. An invited presentation, Mexican Gastroenterological Association Meeting. Guadalajara, Mexico. December 1984.
55. Dajani EZ: Recent advances in the pathophysiology of peptic ulcer disease. An invited presentation, European Association for Gastroenterology and Endoscopy, 17th Congress. Berlin, West Germany. March 1985.
56. Dajani EZ, Bianchi RG, Colton DG, Callison DA, Driskill DR, Phillips EL, Kessler L, Gullikson GW, Woods EM, Collins PW, Pappo R: Perspectives on the pharmacology of misoprostol. An invited presentation, Fifth International Conference on Experimental Ulcer. Boston, Massachusetts. May 1985. Dig Dis Sci 30: 371, 1985.
57. Assad RT, Dodd DC, Dajani EZ: Effect of misoprostol, a prostaglandin E₁ analog, on epithelial proliferation of canine fundic mucosa. Gastroenterology 88: 1310, 1985.
58. Assad RT, Dodd DC, Dajani EZ: Effects of misoprostol, a prostaglandin E₁ analog, on DNA synthesis of canine fundic mucosa. Gastroenterology 88:1310, 1985.

59. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Adaptive cytoprotection of the human gastric mucosa in response to ethanol injury. *Gastroenterology* 88:1496, 1985.
60. McGuigan JE, Chang Y, Deysach L, Dajani EZ: Serum gastrin in patients with duodenal ulcer treated with misoprostol. *Gastroenterology* 88:1496, 1985.
61. Pitzele BS, Yu SS, Hamilton RW, Moorman AE, Gullikson GW, Bianchi RG, Palicharla P, Dajani EZ: Potential antisecretory antidiarrheals, alpha-2 adrenergic agonists related to clonidine. Amer Chem Soc. Chicago, Illinois. September 1985.
62. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Comparative cytoprotection against ethanol-induced gastric mucosal damage: Misoprostol vs. cimetidine. *Amer J of Gastroenterology* 80: 860, 1985.
63. Larsen KE, Dajani EZ, Muka M: Effects of misoprostol, 16, 16-dimethyl PGE₂ and cimetidine on mucosal blood flow and oxygen consumption in the dog ex vivo gastric chamber. *Dig Dis Sci* 31:142S, 1986.
64. Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Comparative effects against alcohol insult: Misoprostol vs. cimetidine. *Dig Dis Sci* 31:142S, 1986.
65. McGuigan JE, Chang Y, Dajani EZ: Effect of misoprostol, an antiulcer prostaglandin, on serum gastrin in patients with duodenal ulcer. *Dig Dis Sci* 31:PS120, 1986.
66. Dajani EZ: Pharmacology of misoprostol. Three lectures delivered in Birmingham, Leeds and London, U.K., as part of regional continuing medical education symposia entitled "Prostaglandins in Peptic Ulcer." February 1986.
67. Dajani EZ: Cytoprotection and acid peptic diseases. An invited presentation, European Association for Gastroenterology and Endoscopy, 18th Congress. Berlin, West Germany. March 1986.
68. Gullikson GW, Anglin C, Kessler L, Smeach S, Bauer R, Dajani EZ: Misoprostol prevents aspirin-induced changes in potential difference and associated damage in canine Heidenhain pouches. An invited presentation, Canadian Association of Gastroenterology. Toronto, Canada. April 1986.
69. Dajani EZ: The role of prostaglandins in the maintenance of mucosal integrity. An invited presentation, Canadian Association of Gastroenterology. Toronto, Canada. April 1986.
70. Dajani EZ: Prostaglandins and their actions on the gastrointestinal tract. Royal Australian College of Physicians Satellite Seminar on Prostaglandins. Hobart, Tasmania. May

1986.

71. Dajani EZ: Prostaglandins: Pharmacology, mechanisms and applications in acid peptic diseases. An invited presentation, Seventh Icelandic Congress of Internal Medicine. Reykjavik, Iceland. May 1986.
72. Dajani EZ: Perspective on the gastric antisecretory effects of misoprostol in man. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
73. Dajani EZ: Gastrointestinal cytoprotective activities of misoprostol: Clinical efficacy overview. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
74. Reimann HJ, Wendt P, Bluemel G, Schmidt U, Ohe MVD, Dajani EZ, Wehrschütz E: Misoprostol prevents damage to the gastroduodenal mucosa by stabilizing the mast cells. Sixth International Conference on Prostaglandins and Related Compounds. Florence, Italy. June 1986.
75. Dajani EZ: Clinical cytoprotective actions of misoprostol. An invited presentation, Italian Society of Gastroenterology. Verona, Italy. June 1986.
76. Dajani EZ: Prostaglandins in acid peptic disorders. An invited lecture presented at a post-graduate course sponsored by the European Society of Gastroenterology and Endoscopy. Cologne, W. Germany. October 1986.
77. Dajani EZ: Misoprostol: Pharmacology, mechanism and applications in peptic ulcer disease. An invited lecture presented at a symposium entitled "International Symposium on Cytoprotection of the Gastroduodenal Mucosa," Inter-American Society of Clinical Pharmacology and Therapeutics/Latin American Association of Pharmacology. Buenos Aires, Argentina. November 1986.
78. Dajani EZ: Overview of misoprostol clinical safety. An invited lecture presented at a symposium entitled "Prostaglandins and Peptic Ulcer Disease," Hong Kong Society of Internal Medicine. Hong Kong. December 1986.
79. Dajani EZ: Pharmacology of misoprostol: Antisecretory plus mucosal protective activity for an antiulcer agent. An invited lecture presented at the European Society of Gastroenterology and Endoscopy, Milan, Italy, June 1986. Italian Journal of Gastroenterology 19 (Suppl. 3): 19S, 1987.
80. Dajani EZ: Prostaglandins in gastroenterology. An invited presentation. Chinese Society

of Gastroenterology. Kunming, People's Republic of China. November 1987.

81. Dajani EZ: Prostaglandins: An update. An invited presentation. American College of Physicians Post Graduate Course. Keystone, Colorado. February 1988.
82. Dajani EZ: Prostaglandins and NSAIDs gastropathy. An invited presentation. Pakistan Society of Gastroenterology and Gastrointestinal Endoscopy. Rawalpindi, Pakistan. March 1988.
83. Dajani EZ: Prostaglandins in gastroenterology. An invited presentation. European Society of Gastroenterology. Milan, Italy. April 1988.
84. Dajani EZ, McGuigan JE, Chang Y: Effect of the antiulcer prostaglandin misoprostol on serum gastrin in patients with duodenal ulcer. *Postgraduate Medical J* 64: 79(Abstract), 1988.
85. Dajani EZ: Prostaglandins and mucosal protection: An update. An invited presentation. Amer Association of Colleges of Pharmacy. Chicago, Illinois. July 1988.
86. Dajani EZ, Lanza F: Endoscopic comparison of the protective effects of misoprostol, cimetidine and sucralfate on nonsteroidal anti-inflammatory drugs induced gastrointestinal mucosal injury. *Endoscopy* 20: 83 (Abstract), 1988.
87. Dajani EZ: Prostaglandins and NSAIDs gastropathy. An invited presentation. 1988 International Congresses of Gastroenterology and Digestive Endoscopy. Rome, Italy. September 1988.
88. Dajani EZ: Prostaglandins. An invited presentation. The USSR Cardiology Research Center at the USSR Academy of Medical Sciences. Moscow, USSR. February 1989.
89. Dajani EZ: Protective and therapeutic effects of prostaglandins. An invited presentation given at a Symposium entitled "NSAID Damage of the Upper Gastrointestinal Tract." Third Interscience World Conference on Inflammation. Monte Carlo, Monaco. March 1989.
90. Dajani EZ: Prostaglandins and nonsteroidal anti-inflammatory drugs: Pharmacology and mechanism of action. An invited presentation. Prostaglandins Telesymposium. University of Puerto Rico. San Juan, Puerto Rico. May 1989.
91. Dajani EZ: Prostaglandins in surgical diseases. An invited presentation. Department of Surgery. Rush-Presbyterian St. Lukes Medical Center. Chicago, Illinois. June 1989.
92. Dajani EZ: Overview on the mechanisms of cytoprotection by misoprostol. An invited presentation at the International Symposium on Cell Injury and Cytoprotection. Harvard Medical School. Boston, Massachusetts. July 1989.

93. Dajani EZ: Prostaglandins and the esophagus: Pharmacological and therapeutic perspectives. An invited presentation. International Symposium on Esophageal Diseases. Taormina, Italy. September 1989.
94. Dajani EZ: Prostaglandins and nonsteroidal anti-inflammatory drugs: Pharmacology, mechanisms of action and future prospects. An invited presentation. International Symposium on Esophageal Diseases. Taormina, Italy. September 1989.
95. Dajani EZ: Prostaglandins and mucosal protection: Current and future perspectives. Visiting Professor Lecture Series, Department of Pharmacology and Toxicology. Purdue University, West Lafayette, Indiana, November 1989.
96. Downie WW, Dajani EZ: NSAID-induced gastropathy: Treatment. Second International Congress of Rheumatology. Manila, Philippines. December 1989.
97. Dajani EZ: Prostaglandins: Visiting Professor. Departments of Medicine and Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, December 1989.
98. Dajani EZ: Prostaglandins and gastroenterology. An invited presentation. Louisiana Gut Club, New Orleans, Louisiana, February 1990.
99. Dajani EZ: Prostaglandins: Current and future perspectives regarding gastric mucosal protection. American College of Physicians. Post Graduate Course, Keystone, Colorado, February 1990.
100. Dajani EZ: Historical perspectives on the discovery and development of misoprostol: A pharmacologist odyssey. An invited presentation. Second International Symposium on Experimental and New Therapeutic approaches to Ulcer Diseases. Pecs, Hungary, July 1990.
101. Dajani EZ: Pharmaceutical industry perspectives on the discovery and development of antiulcer drugs. Chairman of a Round Table Discussion. Presented at the Second International Symposium on Experimental and New Therapeutic Approaches to Ulcer Disease. Pecs, Hungary, July 1990.
102. Dajani EZ: Prostaglandins: Current and future medical developments. An invited presentation. Departments of Medicine and Surgery, Hines Veteran Administration Medical Center. Hines, Illinois, July 1990.
103. Dajani EZ: Prostaglandins: Past, present and future. An invited presentation celebrating the tenth anniversary of Donald E. Wilson, MD as a Chairman of the Department of Medicine, State University of New York, Health Science Center, Brooklyn, NY, September, 1990.

104. Agrawal NM, Dajani EZ, Stromatt S, Brown J: Misoprostol vs. sucralfate for the prophylaxis of NSAID-induced gastric mucosal damage: Result of acute and chronic administration. *Amer J Gastroenterol* 85 (9): 1228 (Abstract), 1990.
105. Dajani EZ: Prostaglandins in acid peptic disorders. An invited presentation. Second Symposium on Experimental Ulcer Disease. Otocec (Slovenia), Yugoslavia, November 1990.
106. Dajani EZ: Prostaglandins in acid peptic disorders: An overview of the worldwide clinical experience: An invited lecture. American College of Physicians Post Graduate Course, Keystone, Colorado, February 1991.
107. Agrawal NM, Stromatt S, Dajani EZ: Comparative efficacy of misoprostol and sucralfate in preventing gastric ulcers in patients on chronic NSAIDs therapy: Role of gastric erosion as a predictor for the development of ulcers. Seventh International Conference on Experimental Ulcer. Berlin, Germany, October 1991.
108. Dajani EZ, Agrawal NM: Prevention of NSAID-induced gastric damage: Effect of prostaglandins and mucosal coating compounds. Joint Meeting of the Mediterranean Society of Clinical Pharmacology and the Italian Society of Gastroenterology. Venice, Italy, October, 1991.
109. Agrawal NM, Dajani EZ: Misoprostol is superior to sucralfate in preventing NSAID-induced gastric ulcer in patients with osteoarthritis: Importance of erosions. *J Association for Academic Minority Physicians* 2:179, 1991.
110. Agrawal N, Meckstroth S, Dajani EZ: Clinical significance of gastric erosions as a predictor of NSAID-induced ulcers. *Gastroenterology* 102:A1, 1992.
111. Dajani EZ: Clinical use of prostaglandins in ulcer therapy. An invited presentation. FASEB/AGA Summer Research Conference entitled "Molecular Basis of Gastric Mucosal Defense." Copper Mountain, Colorado, July 1992.
112. Dajani, EZ: Predictive Models For the Evaluation of Anti-ulcer and Cytoprotective Drugs in Healthy Human Subjects. An invited presentation. Italian Society of Pharmacology: Clinical Pharmacology Section, Udine, Italy, September 1993.
113. Dajani, EZ: Prostaglandins in Gastroenterology: An Update. Invited presentation. Second Osaka International Symposium on Gastroenterology. Osaka, Japan, November 1993.
114. Dajani, EZ: Prostaglandins in Medicine. Visiting Professor Lecture Series. Invited presentation. Osaka City University Medical School. Osaka, Japan, November 1993.

115. Kobayashi K, Dajani EZ, Itoh M, Arakawa T: Second Osaka International symposium on Gastroenterology: Symposium Synopsis. *Dig Dis Sci* 39 (4): 897-898, 1994.
116. Dajani EZ, Agrawal NM: Prevention and treatment of ulcers induced by nonsteroidal anti-inflammatory drugs. Invited Presentation. 8th International Conference on Ulcer Research. Kyoto, Japan, November 1994. An abstract of this presentation was published in *Digestion* 55 (suppl 2): 7, 1994.
117. DaCosta J, Vega KJ, Trotman BW, Cunniff D, Dajani EZ: Topical misoprostol therapy for idiopathic HIV esophageal ulceration. *Am J Gastroenterol* 91: 1886, 1996.
118. Vega KJ, DaCosta J, Bollu J, Trotman BW, Kloser P, Cunnif D, Dajani EZ: Topical misoprostol therapy for HIV idiopathic esophageal ulceration: Case report and literature review. *J Association for Academic Minority Physicians* 7 (4): XXIX, 1996.
119. Dajani EZ: NSAIDs and *H. pylori* in peptic ulcers. Is there a connection? An invited presentation. Ministry of Public Health, Abu Dhabi, United Arab Emirates, December 1997.
120. Dajani EZ: Treatment and prevention of NSAID-induced ulcers. An invited presentation. Ministry of Public Health, Abu Dhabi, United Arab Emirates, December 1997.
121. Larsen KR, Dajani EZ, Dajani NE, Dayton MT: Effects of tolcapone and carbidopa/L-DOPA on intestinal electrolyte and fluid transport in dogs. *Gastroenterology* 114: SO135, 1998.
122. Dajani EZ, Taylor J, Dajani NER, Mir GN: Investigation of the analgesic action of CT-3 [1'1'-dimethyl-heptyl-Delta-8-THC-11-oic acid] in mice: A novel, orally effective cannabinoid. *FASEB Journal* 13: A1108, 1999.
123. Dajani EZ, Larsen KR, Dajani NE, Neelman SD, Taylor MS, Dayton MT: Analgesic and ulcerogenic actions of CT-3 [1'1'-dimethyl-heptyl-Delta-8-THC-11-oic acid] in rats: A novel, orally effective cannabinoid. *FASEB Journal* 13: A1108, 1999.
124. Dajani EZ: NSAIDs, Prostaglandins and gastrointestinal mucosal defense. Invited presentation. Guilio Bertaccini Memorial Symposium, University of Parma, Parma, Italy. May 1999.
125. Dajani EZ: Regulatory considerations in the drug development process. Invited presentation. Chicago Biotech Network. Chicago, Illinois. June 1999.

126. Dajani EZ: Gastroesophageal reflux disease (GERD): Pathophysiological and pharmacological considerations. Invited speaker at a symposium entitled Gastroesophageal Reflux Disease, sponsored by the Association for Academic Minority Physicians, Washington, DC. October 1999.
127. Dajani EZ, Shahwan T, Dajani NE: Prostaglandins and brain-gut axis. Invited presentation. The Second International Symposium on Brain-Gut Axis. Basic and Clinical Aspects. Krakow, Poland. November 2003.
128. Dajani EZ, Konturek SJ: Prostaglandins and brain-gut Axis: Concluding remarks. Invited presentation. The Second International Symposium on Brain-Gut Axis. Basic and Clinical Aspects, Krakow, Poland. November 2003.
129. Dajani EZ: Pharmacological, toxicological and regulatory considerations in medical negligence. Invited presentation. The Medical Negligence Group, American Association of Justice, Vancouver, Canada. July 2010.
130. Dajani EZ: Overview of the pharmacological and therapeutic properties of Nigella Sativa seeds (black seeds): An alternative herbal drug with interesting historical, religious and clinical significance. Invited presentation. Association for Academic Minority Physicians. Naples, Florida. October 2012